Skip to Content

EU Commission fines Teva $500 million for trying to stop rival’s multiple sclerosis drug

KVIA

BRUSSELS (AP) — The European Commission has fined Israeli generic drugmaker Teva more than 460 million euros ($500 million) for improperly seeking to protect the patent for its multiple sclerosis drug and for disparaging a rival company’s development of a competing medicine. The commission said in a statement Thursday that the pharmaceutical firm “misused the patent system to artificially extend patent protection” for its blockbuster MS drug Copaxone. Last year, Teva was ordered to pay $225 million to settle price fixing charges in the U.S. related to sales of a cholesterol-lowering drug.

Article Topic Follows: AP National News

Jump to comments ↓

Associated Press

BE PART OF THE CONVERSATION

KVIA ABC 7 is committed to providing a forum for civil and constructive conversation.

Please keep your comments respectful and relevant. You can review our Community Guidelines by clicking here

If you would like to share a story idea, please submit it here.

Skip to content